<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC52CF74-78A4-409C-B3AD-1BFD4E1B23DF"><gtr:id>EC52CF74-78A4-409C-B3AD-1BFD4E1B23DF</gtr:id><gtr:name>China Medical University Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75450506-2C1F-43CF-9CC3-329FB463511B"><gtr:id>75450506-2C1F-43CF-9CC3-329FB463511B</gtr:id><gtr:name>Erasmus University Rotterdam (EUR)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/51B3600A-54C2-4F6B-99AE-03CD7220EBBA"><gtr:id>51B3600A-54C2-4F6B-99AE-03CD7220EBBA</gtr:id><gtr:name>Royal College of Surgeons in Ireland</gtr:name><gtr:address><gtr:line1>Academic Centre</gtr:line1><gtr:line2>Coombe Women's Hospital</gtr:line2><gtr:line3>Dublin 8</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6EC8608B-1C83-4E6A-87D0-8480E0AC5988"><gtr:id>6EC8608B-1C83-4E6A-87D0-8480E0AC5988</gtr:id><gtr:name>Neuroscience; Lundbeck</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Psychological Medicine</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC52CF74-78A4-409C-B3AD-1BFD4E1B23DF"><gtr:id>EC52CF74-78A4-409C-B3AD-1BFD4E1B23DF</gtr:id><gtr:name>China Medical University Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75450506-2C1F-43CF-9CC3-329FB463511B"><gtr:id>75450506-2C1F-43CF-9CC3-329FB463511B</gtr:id><gtr:name>Erasmus University Rotterdam (EUR)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/51B3600A-54C2-4F6B-99AE-03CD7220EBBA"><gtr:id>51B3600A-54C2-4F6B-99AE-03CD7220EBBA</gtr:id><gtr:name>Royal College of Surgeons in Ireland</gtr:name><gtr:address><gtr:line1>Academic Centre</gtr:line1><gtr:line2>Coombe Women's Hospital</gtr:line2><gtr:line3>Dublin 8</gtr:line3><gtr:region>Outside UK</gtr:region><gtr:country>Ireland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/11E604AE-3915-4673-AEA6-852F7D6BFFD8"><gtr:id>11E604AE-3915-4673-AEA6-852F7D6BFFD8</gtr:id><gtr:name>Wellcome Trust</gtr:name><gtr:address><gtr:line1>183 EUSTON ROAD</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>NW1  2BE</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6EC8608B-1C83-4E6A-87D0-8480E0AC5988"><gtr:id>6EC8608B-1C83-4E6A-87D0-8480E0AC5988</gtr:id><gtr:name>Neuroscience; Lundbeck</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/45CED35A-F9CE-4553-8E0B-C556253CC80A"><gtr:id>45CED35A-F9CE-4553-8E0B-C556253CC80A</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Dobson</gtr:surname><gtr:orcidId>0000-0003-4224-9245</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/668E111E-E53F-4B6E-95EB-A64B58CF6C26"><gtr:id>668E111E-E53F-4B6E-95EB-A64B58CF6C26</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Cleare</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/917736BE-12CC-466B-A760-D4269C15AC8B"><gtr:id>917736BE-12CC-466B-A760-D4269C15AC8B</gtr:id><gtr:firstName>Valeria</gtr:firstName><gtr:surname>Mondelli</gtr:surname><gtr:orcidId>0000-0001-8690-6839</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B8014BD5-7568-445A-9F4C-EDE6F3F70D46"><gtr:id>B8014BD5-7568-445A-9F4C-EDE6F3F70D46</gtr:id><gtr:firstName>Trudie</gtr:firstName><gtr:surname>Chalder</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/3BEFD25A-6821-4504-94B2-9F160DADAA7D"><gtr:id>3BEFD25A-6821-4504-94B2-9F160DADAA7D</gtr:id><gtr:firstName>Matthew</gtr:firstName><gtr:surname>Hotopf</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/48FCFE5A-38FD-463D-86A7-53E5BDC5FD41"><gtr:id>48FCFE5A-38FD-463D-86A7-53E5BDC5FD41</gtr:id><gtr:firstName>Carmine M.</gtr:firstName><gtr:surname>Pariante</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FJ002739%2F1"><gtr:id>F3584D06-7F9C-44E0-A049-B66D08452816</gtr:id><gtr:title>Persistent Fatigue Induced by Interferon-alpha: A New Immunological Model for Chronic Fatigue Syndrome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J002739/1</gtr:grantReference><gtr:abstractText>Chronic fatigue syndrome (CFS) is a medical condition in which patients feel persistently and overwhelmingly tired and run down, both physically and mentally. In addition, they have difficulty with concentration, flu-like symptoms and aches and pains. This condition interferes with daily life activity, and, in some patients, is profoundly disabling. Although many years of research have been conduced on CFS, we still do not know what is causing it. 

One biological system that is involved in CFS is the &amp;quot;immune system&amp;quot;, that is, the system dedicated to fight infections in our body. Indeed, in many cases CFS is triggered by an infection, but then the symptoms continue even after the infection has been eliminated. Specifically, infections are always accompanied by acute fatigue and flu-like symptoms, as a consequence of the infection-driven immune activation; however, in patients with CFS the immune activation and the associated fatigue and flu-like symptoms persist for months or years. Moreover, there is evidence that the immune system is in a state of &amp;quot;hyper-activity&amp;quot; in patients with CFS, as if they were fighting an infective agent, even though they do not have an ongoing infection. 

This project aims to understand exactly this process: how the infection and the acute immune activation evolve into CFS, and what are the risk factors that make this process occur in some individuals but not others. Clearly, trying to study this process in subjects experiencing naturally-acquired infections is very difficult, for the unpredictability of these events. In contrast, we want to model the development of CFS by studying a group of patients that have a pre-existing infection (chronic viral hepatitis C, HCV) and that receive a course of treatment (lasting months) with the immune activator, interferon-alpha (IFN-alpha). IFN-alpha is the treatment of choice for HCV infection. Because it activates the immune system, IFN-alpha also induces fatigue and flu-like symptoms in all patients. Moreover, and of particular relevance for this study, a considerable proportion of patients continue to experience debilitating persistent fatigue, and other symptoms that are similar to CFS, for 6 months or even one year after the cessation of IFN-alpha. This phenomenon strikingly resembles CFS, which, as mentioned above, also persists after the infective/immune trigger has been eliminated. Therefore, we are proposing to use IFN-alpha as a model to understand how an immune trigger induces persistent fatigue even when the initial immune trigger is no longer present. 

To do this, we will assess these patients throughout the many months of IFN-alpha treatment and at 6 months after cessation of treatment, in order to identify those with persistent &amp;quot;post-IFN-alpha-treatment&amp;quot; fatigue, and understand what biological and clinical changes lead to this outcome. Moreover, we will compare these patients with a group of patients with CFS and with a group of healthy individuals, conducting the same biological and clinical assessment. We will measure changes occurring in blood hormones that are relevant to the immune function, such as &amp;quot;cytokines&amp;quot; and &amp;quot;cortisol&amp;quot;. In addition, we will asses changes in measures of well-being, including physical fitness, concentration, sleep and mood. 

We are confident that creating and validating this model of CFS will generate a host of future studies aimed at improving the health of people with CFS. For example, we will be able to build a check-list of blood measures that could predict who will, and who will not, develop CFS; we will test novel treatments for &amp;quot;post-IFN-alpha-treatment&amp;quot; fatigue, facilitated by the fact that these patients are homogeneous in their clinical background, and then extend these treatments to patients with CFS; and, finally, we will truly understand what happens in the body during the development of CFS, and thus identify novel therapeutic approaches to interrupt this development.</gtr:abstractText><gtr:technicalSummary>We propose to model chronic fatigue syndrome (CFS) by studying patients taking interferon-alpha (IFN-alpha) for chronic viral hepatitis C (HCV) infection. IFN-alpha treatment leads to acute fatigue in the majority of patients. Most importantly, a proportion of patients continue to experience persistent fatigue, together with other CFS-like-symptoms, for many months after the cessation of treatment, that is, in the absence of the pro-inflammatory stimulus. This phenomenon strikingly resembles CFS, which also persists after the viral/immune trigger has been eliminated. 

In order to develop this as a model of CFS, in our three-year project we want to:
1) assess a cohort (n=100) of patients throughout the IFN-alpha treatment and at 6 months after cessation of treatment, and identify the group who develop the persistent post-treatment fatigue (expected n=50); 
2) validate this model, by comparing the clinical and biomarkers profiles in patients who experience persistent post-treatment fatigue, patients with CFS (n=50), and healthy controls (n=50);
3) identify the risk factors and the biomarkers trajectories (before and during IFN-alpha treatment) that identify those patients who will later experience persistent post-treatment fatigue. 

We will measure: fatigue, mood, and other CFS-like symptoms; medical and psychiatric history; childhood and recent stressors; social support; illness and treatment perceptions; physical fitness; quality of life; and occupational function. Moreover, we will measure blood biomarkers: serum cytokines; cortisol at awakening and during the day; and leukocytes gene expression.

The project will build onto an existing pilot study in HCV patients, an established collaboration with Liver Units across London, and the research-led clinical service for CFS patients at King's College Hospital. Thus, the project has great chances of success.</gtr:technicalSummary><gtr:potentialImpactText>Our research on chronic fatigue syndrome (CFS) will benefit health and biological scientists; policy makers; stakeholders in health care; the interested lay public (especially those with a personal investment in understanding CFS), and, finally, patients with CFS. 

Social and health scientists will benefit from our data: we will explain the mechanisms underlying the development of chronic fatigue, offer novel aetiological hypotheses to be confirmed in CFS patients, identify a group who are particularly indicated to test novel therapeutic interventions, and suggest new potential biological targets for the pharmacological treatment of CFS. 

Policy makers will benefit from the evidence offered by our study: it will guide them in prioritising resources, in the difficult times ahead, by identifying important stages in the development of chronic fatigues and hence where and when to deliver screening and intervention programmes.

Stakeholders will benefit from understanding what happens to people while they are developing chronic fatigue: charities, non-governmental organisations, and regulatory bodies, all aimed at improving the clinical and social outcomes of CFS patients, will want to know how health, well-being, quality of life and occupational functioning is impacted by changes in biology and behaviour, and how these people can thus be helped. 

Finally, the lay public, and especially patients and carers who have been personally touched by CFS, will benefit from all of our work: a non-stigmatising approach based on a sound biological basis, and an explanatory model that is not deterministic and that emphasises not only risk factors but also the protective factors that could be sought out.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-08-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>373075</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>Drawing deeply from her personal experience, the artist Lynn Lu has spent some time during the development process of a performance for the CCLAP Festival with Professor Carmine Pariante, and his team at King's College London. Their research has found a clear link between mothers with postnatal depression not adequately nurturing their children and these children in time becoming themselves mothers who suffer from postnatal depression.


At Deptford Lounge, the artist will create a safe space, one that she would have liked to have had, as a mother with postnatal depression. This safe space is offered to all mothers, as well as for anyone who might need an experience of nurturing. Together the artist and participants will put in words their darkest thoughts and feelings that have not been voiced. The anonymous texts will then be sealed in palm-sized clay envelops, and fired for strength / privacy / resilience. These accumulating tablets will be exhibited throughout the week. Participants will be invited to be cocooned and rocked in a wide fabric hammock for as long as they wish - as if in the womb, or a rockabye baby. In doing so, they will listen to a RECORDING OF THE INTERVIEW BETWEEN PROFESSOR PARIANTE AND THE ARTIST, which has been digitally modified so to make the words unintelligeble and similar to relaxing music. 

This performance will take place at Deptford Lounge.
Full schedule for CCLAP 2015.</gtr:description><gtr:id>57FD628E-492C-4B64-B4B8-08783917AA62</gtr:id><gtr:impact>The recording was used in the performance, as above, so was publicly used.</gtr:impact><gtr:outcomeId>56e145d81b2e16.82177897</gtr:outcomeId><gtr:title>Recording for live performance of artist Lynn Lu</gtr:title><gtr:type>Performance (Music, Dance, Drama, etc)</gtr:type><gtr:url>http://cclap.me/2015/10/26/cclap-2015-lynn-lu-the-hand-that-rocks-the-cradle/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Wellcome Trust Neuroimmunology Consortium</gtr:description><gtr:id>2FA11BC1-D500-48D3-8AA9-DC88DA9098C0</gtr:id><gtr:impact>Data collection, publications (all still in preparation), novel potential targets for antidepressants discovery</gtr:impact><gtr:outcomeId>56dfcadb0649d5.19613856-2</gtr:outcomeId><gtr:partnerContribution>They participate to the research strategy</gtr:partnerContribution><gtr:piContribution>A research consortium; we recruit and select patients and deliver research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>China Medical University Hospital</gtr:collaboratingOrganisation><gtr:country>Taiwan</gtr:country><gtr:department>Department of Psychiatry and Mind-Body Interface Research Centre</gtr:department><gtr:description>Department of Psychiatry and Mind-Body Interface Research Centre, China Medical University Hospital, Taichung, Taiwan</gtr:description><gtr:id>09CE0B73-711F-45D1-A551-3D64C363E187</gtr:id><gtr:impact>Many publications have arisen from this collaboration, built on work conducted both in London and in Taiwan: PMID: 18370571; 17888811; 17591516; 17503999; 17070845; 17017838; 20034614.</gtr:impact><gtr:outcomeId>53C7CA5475E-1</gtr:outcomeId><gtr:partnerContribution>Research collaboration with Dr. Su</gtr:partnerContribution><gtr:piContribution>Exchange visit between Dr. Su (Taiwan) and Dr. Pariante</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Neuroscience; Lundbeck</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>Wellcome Trust Neuroimmunology Consortium</gtr:description><gtr:id>4F30BDDD-1B62-4CDD-AC41-00D92E07682A</gtr:id><gtr:impact>Data collection, publications (all still in preparation), novel potential targets for antidepressants discovery</gtr:impact><gtr:outcomeId>56dfcadb0649d5.19613856-3</gtr:outcomeId><gtr:partnerContribution>They participate to the research strategy</gtr:partnerContribution><gtr:piContribution>A research consortium; we recruit and select patients and deliver research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Erasmus University Rotterdam</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Erasmus University, Rotterdam</gtr:description><gtr:id>9A0162B4-E742-4E9D-8045-104CE232A8C7</gtr:id><gtr:impact>Papers and new grant applications.</gtr:impact><gtr:outcomeId>jYVu1Etm9Tt-1</gtr:outcomeId><gtr:partnerContribution>Training in laboratory expertise and exchange of data</gtr:partnerContribution><gtr:piContribution>Exchange of researchers and data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Queen's Medical Research Institute Edinburgh</gtr:department><gtr:description>Queen's Medical Research Institute, University of Edinburgh, UK</gtr:description><gtr:id>82549C8A-D9BF-45E9-8A7B-9CE67A3E0B96</gtr:id><gtr:impact>PMID: 17356567</gtr:impact><gtr:outcomeId>5F29E8AB11E-1</gtr:outcomeId><gtr:partnerContribution>Collaboration with Professor Seckl in an animal study</gtr:partnerContribution><gtr:piContribution>I have been in Edinburgh several times to plan the experiments with the collaborators. The collaborators have funded and conducted the study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Pharmaceutical Science Research Division, Kings College London (KCL), UK</gtr:description><gtr:id>5D8B4ABC-EE3B-4417-A3D8-D59C606A2B96</gtr:id><gtr:impact>PMID: 18556350, 17356567, 20881247</gtr:impact><gtr:outcomeId>6A78FEE9909-1</gtr:outcomeId><gtr:partnerContribution>Collaboration with Dr. Sarah Thomas in joint supervision of a PhD student and conducting animal studies.</gtr:partnerContribution><gtr:piContribution>The experiments on blood-brain barrier permeability have been conducted in the collaborator's laboratory but funded by this grant.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Social Genetic and Developmental Psychiatry Centre (SDGP)</gtr:department><gtr:description>MRC Social Genetic and Developmental Psychiatry Centre (SDGP</gtr:description><gtr:id>E0F0240A-BB17-4A5F-BC84-A657AD822BF9</gtr:id><gtr:impact>PMID 19751968, 19074533, 18458677, 19996051, 18391129, 17229839, 20157309</gtr:impact><gtr:outcomeId>CA9A5AC1826-1</gtr:outcomeId><gtr:partnerContribution>Development of a parallel clinical and pre-clinical research strategy linked with the current proposal.</gtr:partnerContribution><gtr:piContribution>Collaboration with Dr. Aitchison and Professors Moffitt and Caspi.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Wellcome Trust Neuroimmunology Consortium</gtr:description><gtr:id>C27AE624-60F6-4A2B-9B31-5A630682FF6C</gtr:id><gtr:impact>Data collection, publications (all still in preparation), novel potential targets for antidepressants discovery</gtr:impact><gtr:outcomeId>56dfcadb0649d5.19613856-4</gtr:outcomeId><gtr:partnerContribution>They participate to the research strategy</gtr:partnerContribution><gtr:piContribution>A research consortium; we recruit and select patients and deliver research</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Psychiatry (GSK)</gtr:department><gtr:description>MRC Immunopsychiatry Consortium</gtr:description><gtr:id>168E1703-F024-4C94-AA14-1EEE4A6FB4E5</gtr:id><gtr:impact>Data exchange, publications (in preparation)</gtr:impact><gtr:outcomeId>56dfc92c736994.17461304-2</gtr:outcomeId><gtr:partnerContribution>Funding of studies, contribution to research strategy and design</gtr:partnerContribution><gtr:piContribution>Design of studies, execution of studies and experiments</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRC Immunopsychiatry Consortium</gtr:description><gtr:id>B072794C-8D72-458F-85DB-8B6E3FE8B188</gtr:id><gtr:impact>Data exchange, publications (in preparation)</gtr:impact><gtr:outcomeId>56dfc92c736994.17461304-1</gtr:outcomeId><gtr:partnerContribution>Funding of studies, contribution to research strategy and design</gtr:partnerContribution><gtr:piContribution>Design of studies, execution of studies and experiments</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Wellcome Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wellcome Trust Strategic Award</gtr:department><gtr:description>Wellcome Trust Neuroimmunology Consortium</gtr:description><gtr:id>DCCCBFE5-5225-4E5F-9C8A-9229D208C874</gtr:id><gtr:impact>Data collection, publications (all still in preparation), novel potential targets for antidepressants discovery</gtr:impact><gtr:outcomeId>56dfcadb0649d5.19613856-1</gtr:outcomeId><gtr:partnerContribution>They participate to the research strategy</gtr:partnerContribution><gtr:piContribution>A research consortium; we recruit and select patients and deliver research</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Janssen Pharmaceuticals</gtr:department><gtr:description>Janssen Pharmaceuticals</gtr:description><gtr:id>08EE2246-9092-4E6D-9119-1B7BC2EE685E</gtr:id><gtr:impact>- a fully funded research programme on depression and inflammation
- additional grant applications to MRC and the Wellcome</gtr:impact><gtr:outcomeId>rrPnj3mR99p-1</gtr:outcomeId><gtr:partnerContribution>Shared academic leadership and full funding of research programma</gtr:partnerContribution><gtr:piContribution>A joint academic-pharma collaboration that has brought approximately &amp;pound;680,000 in research funding</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Clinical Sciences</gtr:department><gtr:description>University of Bristol</gtr:description><gtr:id>C7187DD3-F347-4374-B60F-D9E898525162</gtr:id><gtr:impact>PMID 19336786, 18675469, 17356567, 17016711, 20558006</gtr:impact><gtr:outcomeId>E19568BBBD0-1</gtr:outcomeId><gtr:partnerContribution>Scientific collaboration with Professor Stafford Lightman</gtr:partnerContribution><gtr:piContribution>We have planned together animal and human research funded by this grant.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Academic Psychiatry and Regional Affective Disorders Service</gtr:department><gtr:description>Department of Psychiatry, Newcastle University, UK</gtr:description><gtr:id>21F89F48-20B3-4797-9FD2-F6FCB891D750</gtr:id><gtr:impact>The study has been completed and a publication is currently in preparation.</gtr:impact><gtr:outcomeId>F23EDB44101-1</gtr:outcomeId><gtr:partnerContribution>Collaboration with Dr. H. McAllister-Williams for a clinical study on EEG.</gtr:partnerContribution><gtr:piContribution>A study was conducted on EEG and cortisol in the collaborator's laboratory; the study was funded by this grant and was in the original research proposal.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal College of Surgeons in Ireland</gtr:collaboratingOrganisation><gtr:country>Ireland, Republic of</gtr:country><gtr:department>Department of Psychiatry</gtr:department><gtr:description>Royal College of Surgeons in Ireland</gtr:description><gtr:id>9F99443C-5458-4541-80E7-B79C35CB2621</gtr:id><gtr:impact>PMID: 18562437, 17938637</gtr:impact><gtr:outcomeId>B163EF63588-1</gtr:outcomeId><gtr:partnerContribution>Collaboration on in vitro models based on present grant</gtr:partnerContribution><gtr:piContribution>Scientific collaboration on in vitro models relevant to the present project</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Antidepressants may not be perfect, but they DO save lives: Expert reveals how life-changing the drug can be when used in the right way</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9A2BE29C-2628-48BD-A5AA-46D99DA31F9B</gtr:id><gtr:impact>Professor Carmine Pariante has treated thousands of patients with depression Despite expert claims the pills have devastating side-effects, he stands by them
They work when used correctly, especially alongside psychological therapy

Read more: http://www.dailymail.co.uk/health/article-4243156/Antidepressants-not-perfect-save-lives.html#ixzz4awYvDP2Q</gtr:impact><gtr:outcomeId>58c2dcc379ed42.60218269</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.dailymail.co.uk/health/article-4243156/Antidepressants-not-perfect-save-lives.html</gtr:url><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Interview for BBC Radio 4 Programme</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>82464713-0930-4FC5-84D6-C420E1D40BE6</gtr:id><gtr:impact>BBC health reporter James Gallagher explores the increasing body of evidence that a dysfunctional immune system is responsible for the depression or psychotic illness experienced by hundreds of thousands, perhaps millions, of people in the UK. James talks to the psychiatrists investigating this new understanding of mental illness and to people who may benefit from treatments aimed at the immune systems rather than their brain cells.

&amp;quot;I believe this is one of the strongest discoveries in psychiatry in the last twenty years&amp;quot;, says Professor Carmine Pariante of his and other research on the immune system and depression. &amp;quot;It allows us to understand depression no longer as just a disorder of the mind and not even a disorder of the brain, but a disorder of the whole body. It shifts conceptually what we understand about depression.&amp;quot;

James also talks to New York journalist Susannah Cahalan. She began to experience paranoid delusions and florid hallucinations when her immune system made damaging antibodies against part of the molecular circuitry in her brain. Treatment to eliminate the antibodies prevented her committal to psychiatric hospital. Psychiatrist Professor Belinda Lennox at the University of Oxford says she has evidence that a significant proportion of people presenting for the first time with psychotic symptoms are victims of a similar autoimmune problem.

Producer: Rachael Buchanan and Andrew Luck-Baker.</gtr:impact><gtr:outcomeId>58c2db9b5aba44.06284534</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.bbc.co.uk/programmes/b07pj2pw</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press conference</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E93569ED-68EE-4DEB-8750-ED150091A27B</gtr:id><gtr:impact>Press conference associated with a symposium on depression

Private interviews with a radio, description on news websites</gtr:impact><gtr:outcomeId>074BE7034D9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Symposium at the Royal College of Psychiatrists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>788E0FBE-CC12-4F1A-9F77-5EBB73E8AE0E</gtr:id><gtr:impact>S33 Predicting response to antidepressants: Is it possible? Wednesday 1st of July 2015
Chair: Dr Hamish McAllister-Williams, Newcastle University 

HPA axis and inflammatory cytokines *Professor Carmine Pariante, Institute of Psychiatry, London 

Cognition and emotional processing Professor Catherine Harmer, University of Oxford EEG variables 
Dr Hamish McAllister-Williams, Newcastle University


S54 Inflammation &amp;amp; Mental Health: An overview of perinatal and later life infection/inflammation on risk for common mental illnesses - - Thursday 2nd of July
Chair: Prof Hugo Critchley, Brighton &amp;amp; Sussex Medical School 

Early-life infection alters glial function and increases susceptibility to cognitive and neuropsychiatric disorders including schizophrenia and
autism 
Dr Staci Bilbo, Duke University 

Can blood and brain MRI biomarkers be used to identify patients most likely to benefit from 'anti-inflammatory' treatments?
Dr Neil Harrison, University of Sussex

Update on the current evidence supporting a role for 'anti-inflammatory' agents in the management of treatment resistant depression *Professor Carmine Pariante, Kings College London</gtr:impact><gtr:outcomeId>56dfcd9cbc9d44.11851953</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cheltenham Science festival</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6806AC02-35B4-41A1-8CA1-36ADCEC3BD18</gtr:id><gtr:impact>Many questions and subsequent emails

I was reached by journalists for further interviews</gtr:impact><gtr:outcomeId>545b902676d3e7.31327379</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personal blog on the Huffington Post</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A45F0028-708C-4A3B-A938-D97122BF4459</gtr:id><gtr:impact>regular entry blogs on topics related to mental health</gtr:impact><gtr:outcomeId>56dfcd24198be3.29683875</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.huffingtonpost.co.uk/carmine-pariante/</gtr:url><gtr:year>2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Daily Mail</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DC03B9AC-14E1-4A2F-81AE-C53DDB52D0AE</gtr:id><gtr:impact>Interview of perinatal depression

Attracted public interest</gtr:impact><gtr:outcomeId>42103EF3DA4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Immunopsychiatry consortium</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6E2676CF-EC93-4BF0-A129-AE8F5B3DF0F5</gtr:id><gtr:outcomeId>545b931ebe83d3.66319437</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Marie Curie</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>204EB865-85DD-46CD-BAD2-D3E8CEE9AD36</gtr:id><gtr:outcomeId>M5y4eWGJqTs</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>182000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Post-doctorate fellowship to Martin Egeland to study inflammation and neurogenesis in rodents</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>0C3DC96C-EA3A-4FEA-9EB3-6779A2CA8290</gtr:id><gtr:outcomeId>545b8eb24d7d43.18244812</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>680000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Janssen Pharmaceuticals</gtr:department><gtr:description>Jannsen Investigator Initiated</gtr:description><gtr:end>2017-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>F122597A-32A4-4B0B-B9F5-D005CA894A25</gtr:id><gtr:outcomeId>SzHmhAhJjUF</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Institutional Strategic Support Fund</gtr:department><gtr:description>Wellcome Trust Neuroimmunology Consortium</gtr:description><gtr:end>2019-12-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>04B7C33C-5D1A-4B4D-8913-D268060A8018</gtr:id><gtr:outcomeId>545b92c1bd1fe7.60600787</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>680000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Janssen Pharmaceutica</gtr:department><gtr:description>To investigate inflammation-related cellular models of depression</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>74022C2F-1001-4E73-BD38-395AAA516018</gtr:id><gtr:outcomeId>545b8f1d971055.75475080</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>BAP Antidepressant Guideliness</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4F8878BF-1B77-4757-BE6C-EB8E0F048C0E</gtr:id><gtr:impact>Improvement of prescription practice</gtr:impact><gtr:outcomeId>6FF2E1D0668</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>2013 CMO Report on Mental Health - Chapter on Neuroscience</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A6FB73B3-16C4-421E-ACDA-6CF1EA0F8131</gtr:id><gtr:impact>Improved understanding of neuroscience issues relevant to mental health</gtr:impact><gtr:outcomeId>56dfce53234961.59155309</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Validation in a second sample now completed; publication in submission</gtr:description><gtr:id>B2EC58DF-FD39-4290-BA41-7E05730DB4C2</gtr:id><gtr:impact>Improve prediction of antidepressant response and personalised medicine</gtr:impact><gtr:outcomeId>545c07dcd05c34.56389184</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Gene expression levels of inflammatory cytokines as predictor of antidepressant response</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>A test to assess stress hormones secretion that predicts treatment response in depressed patients.</gtr:description><gtr:id>BAB603DE-5109-4733-995B-501CBE404167</gtr:id><gtr:impact>The relevant paper have been published: 19336786, 17016711, 20558006.</gtr:impact><gtr:outcomeId>64BEA6DB152</gtr:outcomeId><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Prednisolone suppression test</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>The genes list obtained by transcriptomics of blood MRNA of patients with depression before and after antidepressant (GENDEP sample) and before and after interferon-alpha treatment (MRC-funded project), both as raw data and as combined gene lists with statistical enrichment for overlapping genes.</gtr:description><gtr:id>44E09EB9-BB23-4233-BAF3-FB7CFAEC44A6</gtr:id><gtr:impact>collaboration and cross validation across independent research groups</gtr:impact><gtr:outcomeId>56e148e40f7ee0.47260550</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Genes list for depression</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have used human neuronal stem cells and human neurones derived from iPSC cells and treated with a host of depressogenic stimuli (cortisol, Il-1, Il-6, interferon-alpha, oxidative stress) and antidepressant strategies (SSRIs, tricyclics, omega-3, anti-inflammatories). This model replicates well established brain cellular phenotypes associated with depression (or, conversely, antidepressant treatment) such as change sin neurogenesis and synaptogenesis, as well as changes in molecular mechanisms that can be replicated in the brain of animal subjected to stress/antidepressants as well as in clinical samples of depressed patients.

1: Egeland M, Zunszain PA, Pariante CM. Molecular mechanisms in the regulation of
adult neurogenesis during stress. Nat Rev Neurosci. 2015 Apr;16(4):189-200. doi: 
10.1038/nrn3855. Review. PubMed PMID: 25790864.


2: Horowitz MA, Wertz J, Zhu D, Cattaneo A, Musaelyan K, Nikkheslat N, Thuret S, 
Pariante CM, Zunszain PA. Antidepressant compounds can be both pro- and
anti-inflammatory in human hippocampal cells. Int J Neuropsychopharmacol. 2014
Oct 31;18(3). pii: pyu076. doi: 10.1093/ijnp/pyu076. PubMed PMID: 25522414;
PubMed Central PMCID: PMC4360247.


3: Anacker C, Cattaneo A, Musaelyan K, Zunszain PA, Horowitz M, Molteni R, Luoni 
A, Calabrese F, Tansey K, Gennarelli M, Thuret S, Price J, Uher R, Riva MA,
Pariante CM. Role for the kinase SGK1 in stress, depression, and glucocorticoid
effects on hippocampal neurogenesis. Proc Natl Acad Sci U S A. 2013 May
21;110(21):8708-13. doi: 10.1073/pnas.1300886110. Epub 2013 May 6. PubMed PMID:
23650397; PubMed Central PMCID: PMC3666742.


4: Anacker C, Cattaneo A, Luoni A, Musaelyan K, Zunszain PA, Milanesi E, Rybka J,
Berry A, Cirulli F, Thuret S, Price J, Riva MA, Gennarelli M, Pariante CM.
Glucocorticoid-related molecular signaling pathways regulating hippocampal
neurogenesis. Neuropsychopharmacology. 2013 Apr;38(5):872-83. doi:
10.1038/npp.2012.253. Epub 2012 Dec 6. PubMed PMID: 23303060; PubMed Central
PMCID: PMC3672002.


5: Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, Thuret
S, Price J, Pariante CM. Interleukin-1?: a new regulator of the kynurenine
pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology. 2012
Mar;37(4):939-49. doi: 10.1038/npp.2011.277. Epub 2011 Nov 9. PubMed PMID:
22071871; PubMed Central PMCID: PMC3280640.


6: Anacker C, Zunszain PA, Cattaneo A, Carvalho LA, Garabedian MJ, Thuret S,
Price J, Pariante CM. Antidepressants increase human hippocampal neurogenesis by 
activating the glucocorticoid receptor. Mol Psychiatry. 2011 Jul;16(7):738-50.
doi: 10.1038/mp.2011.26. Epub 2011 Apr 12. PubMed PMID: 21483429; PubMed Central 
PMCID: PMC3121947.</gtr:description><gtr:id>14F42BE2-E066-4457-B850-098FF7F61F28</gtr:id><gtr:impact>Development of a platform for the potential development of novel antidepressants, with reduction in required use of animals.</gtr:impact><gtr:outcomeId>56e1483cb97165.73366944</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Depression in a dish model</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:url>http://www.pnas.org/content/110/21/8708.long</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>33DBB119-180C-44CC-8F83-B2AFD678D75F</gtr:id><gtr:title>Symptomatic treatment of interferon-a-induced depression in hepatitis C: a systematic review.</gtr:title><gtr:parentPublicationTitle>Journal of clinical psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/207b7b217093050187d7be9e92ef50b3"><gtr:id>207b7b217093050187d7be9e92ef50b3</gtr:id><gtr:otherNames>Baraldi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0271-0749</gtr:issn><gtr:outcomeId>pm_14385_25_22722514</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC74214E-476C-4788-B673-3071B6396CE6</gtr:id><gtr:title>Inflammatory insults and mental health consequences: does timing matter when it comes to depression?</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cda7a2a90b074098386c3d1108bc224e"><gtr:id>cda7a2a90b074098386c3d1108bc224e</gtr:id><gtr:otherNames>Du Preez A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>585d6dbcd2b6e1.93734005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FD0AB0A-53E3-4A70-BB6E-7DEB4F193F3F</gtr:id><gtr:title>Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-? mRNA Levels Accurately Predict Treatment Response in Depressed Patients.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe709bb607ac81a00515e5730f2d2288"><gtr:id>fe709bb607ac81a00515e5730f2d2288</gtr:id><gtr:otherNames>Cattaneo A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>58c2dae5f16957.99349058</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42ED5537-B75F-46B6-BAEF-B3FB58A65C2A</gtr:id><gtr:title>Effects of anti-inflammatory drugs on the expression of tryptophan-metabolism genes by human macrophages.</gtr:title><gtr:parentPublicationTitle>Journal of leukocyte biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0231f99ecb6ee848f539fcf6a2618cd8"><gtr:id>0231f99ecb6ee848f539fcf6a2618cd8</gtr:id><gtr:otherNames>Regan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0741-5400</gtr:issn><gtr:outcomeId>5aa7776754e155.76884763</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AED5A08-36FA-4997-8C77-230645064A69</gtr:id><gtr:title>Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system.</gtr:title><gtr:parentPublicationTitle>Journal of affective disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f14abbadc4a55009b06588cb304e3d2"><gtr:id>5f14abbadc4a55009b06588cb304e3d2</gtr:id><gtr:otherNames>Carvalho LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0165-0327</gtr:issn><gtr:outcomeId>pm_14385_25_23200297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF945D33-59DE-4108-BB41-C009AC518338</gtr:id><gtr:title>Serum and gene expression profile of cytokines in first-episode psychosis.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b4eab02a3fb6a69c47443bab8c18777d"><gtr:id>b4eab02a3fb6a69c47443bab8c18777d</gtr:id><gtr:otherNames>Di Nicola M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>pm_14385_25_22749891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F27A23E9-B2D8-448A-9152-810360FCB7B4</gtr:id><gtr:title>Innate Immune Memory: Implications for Microglial Function and Neuroprogression.</gtr:title><gtr:parentPublicationTitle>Modern trends in pharmacopsychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/199547e25516ba0c4864536f20508b6e"><gtr:id>199547e25516ba0c4864536f20508b6e</gtr:id><gtr:otherNames>Salam AP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0077-0094</gtr:issn><gtr:outcomeId>5aa7776a6080e9.57153795</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>348262D3-6348-4AE9-83CA-9BC2E13C289D</gtr:id><gtr:title>Neuroscience, mental health and the immune system: overcoming the brain-mind-body trichotomy.</gtr:title><gtr:parentPublicationTitle>Epidemiology and psychiatric sciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed324ed08cc08426275f2185160230e5"><gtr:id>ed324ed08cc08426275f2185160230e5</gtr:id><gtr:otherNames>Pariante CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-7960</gtr:issn><gtr:outcomeId>56dfc7113e4101.97923566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7FE4D1F0-61A8-425E-9DA7-EAD71FFB1CC2</gtr:id><gtr:title>The role of immune genes in the association between depression and inflammation: a review of recent clinical studies.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9598dac0f070a1495d014add4be5a574"><gtr:id>9598dac0f070a1495d014add4be5a574</gtr:id><gtr:otherNames>Bufalino C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>pm_14385_25_22580182</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EE766876-A40D-4AB6-9F7F-7E881F04C6E7</gtr:id><gtr:title>Insufficient glucocorticoid signaling and elevated inflammation in coronary heart disease patients with comorbid depression.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51a2d8e205091e65b6b9cdb59daf45cd"><gtr:id>51a2d8e205091e65b6b9cdb59daf45cd</gtr:id><gtr:otherNames>Nikkheslat N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>56dfc713104158.95812872</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54536CD4-AB4F-4006-A4A4-2A8FB200C5DB</gtr:id><gtr:title>Immune mechanisms linked to depression via oxidative stress and neuroprogression.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c40e3f35f984b220d21df7068e2ccc84"><gtr:id>c40e3f35f984b220d21df7068e2ccc84</gtr:id><gtr:otherNames>Bakunina N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>56dfc7140e66b2.42342606</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DFCB7F7-A085-4496-8CFD-D5560A9E0C6B</gtr:id><gtr:title>Withdrawing interferon-a from psychiatric patients: clinical care or unjustifiable stigma?</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74f5e4f71aa1e2fbf2c936973aede158"><gtr:id>74f5e4f71aa1e2fbf2c936973aede158</gtr:id><gtr:otherNames>Spennati A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>pm_14385_25_22975198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0667EE14-B0FE-4119-A4C1-20D4813C79D8</gtr:id><gtr:title>Genetic Contributions of Inflammation to Depression.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69c3aed68c9625297800eab8ea5b4792"><gtr:id>69c3aed68c9625297800eab8ea5b4792</gtr:id><gtr:otherNames>Barnes J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>58c2dae53b2232.30044432</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FA39B710-6BB4-4AC5-A038-F4A2B66D64D4</gtr:id><gtr:title>Transcriptomics in Interferon-a-Treated Patients Identifies Inflammation-, Neuroplasticity- and Oxidative Stress-Related Signatures as Predictors and Correlates of Depression.</gtr:title><gtr:parentPublicationTitle>Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02c248c98d66db73b1fb33ba2706e895"><gtr:id>02c248c98d66db73b1fb33ba2706e895</gtr:id><gtr:otherNames>Hepgul N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0893-133X</gtr:issn><gtr:outcomeId>58c2dae66a1ce1.02932492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81550DD1-53ED-45E2-A283-1717D8D333EC</gtr:id><gtr:title>Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-a.</gtr:title><gtr:parentPublicationTitle>Molecular psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c446fa0bff6f451bac1159a6d51f70cc"><gtr:id>c446fa0bff6f451bac1159a6d51f70cc</gtr:id><gtr:otherNames>Baumeister D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-4184</gtr:issn><gtr:outcomeId>56dfc7132fa883.51408327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0809E733-022B-4365-904E-074C1C2F5F5F</gtr:id><gtr:title>Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation.</gtr:title><gtr:parentPublicationTitle>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed324ed08cc08426275f2185160230e5"><gtr:id>ed324ed08cc08426275f2185160230e5</gtr:id><gtr:otherNames>Pariante CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0924-977X</gtr:issn><gtr:outcomeId>5a31d71e9ea1a4.43943107</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B43085B-D8F0-427D-9824-E28E85F6F80F</gtr:id><gtr:title>Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors.</gtr:title><gtr:parentPublicationTitle>Social psychiatry and psychiatric epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c446fa0bff6f451bac1159a6d51f70cc"><gtr:id>c446fa0bff6f451bac1159a6d51f70cc</gtr:id><gtr:otherNames>Baumeister D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0933-7954</gtr:issn><gtr:outcomeId>pm_540e191e19191ceed</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F491B184-770E-4BCE-8DA7-52155F0BAD6D</gtr:id><gtr:title>Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74a49f7235d5892da9d98b19dd2bb1c4"><gtr:id>74a49f7235d5892da9d98b19dd2bb1c4</gtr:id><gtr:otherNames>Su KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>doi_55faa2aa2444492a</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>379FBBAD-69EF-469E-9B9F-6FFE05AD38ED</gtr:id><gtr:title>Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection.</gtr:title><gtr:parentPublicationTitle>Nutritional neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8c52060bc893b6bd0876d0f5d1d9d31"><gtr:id>c8c52060bc893b6bd0876d0f5d1d9d31</gtr:id><gtr:otherNames>Chang JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1028-415X</gtr:issn><gtr:outcomeId>56dfc711e13bc0.11546226</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>33EA940A-93D9-400D-8F84-0824314F8CDB</gtr:id><gtr:title>Depression and anxiety in patients receiving interferon-alpha: The role of illness perceptions.</gtr:title><gtr:parentPublicationTitle>Journal of health psychology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02c248c98d66db73b1fb33ba2706e895"><gtr:id>02c248c98d66db73b1fb33ba2706e895</gtr:id><gtr:otherNames>Hepgul N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-1053</gtr:issn><gtr:outcomeId>58c2dae5c0f6e4.85964096</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>691DCAF3-ABCE-47A0-A5AF-52393CB14D9A</gtr:id><gtr:title>On the heart, the mind, and how inflammation killed the Cartesian dualism. Commentary on the 2015 Named Series: Psychological Risk Factors and Immune System Involvement in Cardiovascular Disease.</gtr:title><gtr:parentPublicationTitle>Brain, behavior, and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a34bed4dcc674485c8692e22b0bc3da"><gtr:id>2a34bed4dcc674485c8692e22b0bc3da</gtr:id><gtr:otherNames>Mondelli V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0889-1591</gtr:issn><gtr:outcomeId>56dfc712143f83.06894978</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C98ADE86-D43C-4A91-8BDC-F71FDFB14EAF</gtr:id><gtr:title>Fibromyalgia and chronic fatigue: the underlying biology and related theoretical issues.</gtr:title><gtr:parentPublicationTitle>Advances in psychosomatic medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66ca875a171c545c70755a5b7afac19a"><gtr:id>66ca875a171c545c70755a5b7afac19a</gtr:id><gtr:otherNames>Romano GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0065-3268</gtr:issn><gtr:outcomeId>5675e1ac848c4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>408A13F2-4988-4480-AC5B-77A4EFE8815E</gtr:id><gtr:title>Childhood stressors in the development of fatigue syndromes: a review of the past 20 years of research.</gtr:title><gtr:parentPublicationTitle>Psychological medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d5f1d765c97c0d67ba1951fce4655a8"><gtr:id>7d5f1d765c97c0d67ba1951fce4655a8</gtr:id><gtr:otherNames>Borsini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-2917</gtr:issn><gtr:outcomeId>doi_55f98698625ed818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E92725F2-AA4D-4C9A-8DA7-A7713BEA3093</gtr:id><gtr:title>Crosstalk between endocannabinoid and immune systems: a potential dysregulation in depression?</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/da61e6a53f97c00669023f428be815c1"><gtr:id>da61e6a53f97c00669023f428be815c1</gtr:id><gtr:otherNames>Boorman E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>56dfc7127795d4.53355731</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9204F5EF-4934-46FD-ABA5-68DB980EAC0E</gtr:id><gtr:title>The role of inflammatory cytokines as key modulators of neurogenesis.</gtr:title><gtr:parentPublicationTitle>Trends in neurosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d5f1d765c97c0d67ba1951fce4655a8"><gtr:id>7d5f1d765c97c0d67ba1951fce4655a8</gtr:id><gtr:otherNames>Borsini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0166-2236</gtr:issn><gtr:outcomeId>doi_55f9869862557ef8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D6193F5-BCEF-4506-AFBC-E261F82540A9</gtr:id><gtr:title>Psychoneuroimmunology or immunopsychiatry?</gtr:title><gtr:parentPublicationTitle>The lancet. Psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed324ed08cc08426275f2185160230e5"><gtr:id>ed324ed08cc08426275f2185160230e5</gtr:id><gtr:otherNames>Pariante CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2215-0366</gtr:issn><gtr:outcomeId>5675eb5a2b056</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66A0F8A0-7517-4C9C-BE02-57B6B73074BC</gtr:id><gtr:title>Interferon-Alpha Reduces Human Hippocampal Neurogenesis and Increases Apoptosis via Activation of Distinct STAT1-Dependent Mechanisms.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d5f1d765c97c0d67ba1951fce4655a8"><gtr:id>7d5f1d765c97c0d67ba1951fce4655a8</gtr:id><gtr:otherNames>Borsini A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>5aa777697db751.18023392</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J002739/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>986F1CAE-CC43-4D59-8F85-A91971E4C4BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Other</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>